CLLS
Strong SellSinkerCellectis S.A. · Healthcare · France · $342M · Avg Vol: $191K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT CELLECTIS S.A.
Read
Cellectis S.A. is a French clinical-stage biotechnology company pioneering the development of allogeneic, 'off-the-shelf' CAR-T immunotherapies for cancer. The company's competitive moat is built on its proprietary TALEN gene-editing technology, which enables the mass production of gene-edited T-cells from healthy donors. Cellectis operates as a highly innovative biotech pioneer, supported by strategic partnerships with global pharmaceutical leaders like AstraZeneca to advance its oncology pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.2M | 0.8M | 41.5M | 72.9M | 56.1% | 63.8M | 50.3M | 68.6M | -3.0% |
| EPS | -2.33 | -1.77 | -0.41 | -0.67 | — | -0.64 | -0.81 | -0.70 | — |
| Shares | 45.7M | 71.8M | 72.1M | 100.3M | +119.7% | — | — | — | — |
| Debt | 75.8M | 85.1M | 91.5M | 90.7M | 6.2% | 80.3M | — | — | — |
| Equity | 118.0M | 84.7M | 131.0M | 75.9M | -13.7% | — | — | — | — |
| Op CF | -87.4M | -24.7M | 23.0M | -39.4M | — | -41.6M | — | — | — |
| Inv CF | -2.8M | -15.5M | -102.8M | -29.5M | — | — | — | — | — |
| Fin CF | 1.1M | 82.9M | 89.1M | -16.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLLS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLLS | Cellectis S.A.(you) | $342M | 6 | Strong Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| VLA.PA | Valneva SE | $614M | 3 | Strong Sell |
| IPHA | Innate Pharma S.A. | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| DBV.PA | DBV Technologies S.A. | $864M | 6 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
| IVA | Inventiva S.A. | $1.1B | 8 | Strong Sell |
| OSE.PA | OSE Immunotherapeutics SA | $89M | 4 | Strong Sell |
| ABNX.PA | ABIONYX Pharma SA | $100M | 1 | Strong Sell |
Peer medians: ROE -32.6% · P/E 22.9x · Gross margin 69.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.